CELULARITY INC-A (CELU) Stock Price, Quote, News and Overview
NASDAQ:CELU - Nasdaq - US1511902041 - Common Stock - Currency: USD
CELU Quote, Performance and Key Statistics
NASDAQ:CELU (2/21/2025, 8:07:08 PM)
1.68
-0.12 (-6.67%)
The current stock price of CELU is 1.68 USD. In the past month the price decreased by -26.96%. In the past year, price decreased by -63.82%.
CELU Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CELU
Company Profile
Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. The company is headquartered in Florham Park, New Jersey and currently employs 120 full-time employees. The company went IPO on 2019-05-23. The company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. The company develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).
Company Info
CELULARITY INC-A
170 Park Ave
Florham Park NEW JERSEY US
Employees: 120
Company Website: https://celularity.com/
Investor Relations: https://celularity.com/investor-relations/
Phone: 19087682170
CELULARITY INC-A / CELU FAQ
What is the stock price of CELULARITY INC-A today?
The current stock price of CELU is 1.68 USD. The price decreased by -6.67% in the last trading session.
What is the ticker symbol for CELULARITY INC-A stock?
The exchange symbol of CELULARITY INC-A is CELU and it is listed on the Nasdaq exchange.
On which exchange is CELU stock listed?
CELU stock is listed on the Nasdaq exchange.
What is CELULARITY INC-A worth?
CELULARITY INC-A (CELU) has a market capitalization of 37.77M USD. This makes CELU a Nano Cap stock.
How many employees does CELULARITY INC-A have?
CELULARITY INC-A (CELU) currently has 120 employees.
What are the support and resistance levels for CELULARITY INC-A (CELU) stock?
CELULARITY INC-A (CELU) has a resistance level at 2.12. Check the full technical report for a detailed analysis of CELU support and resistance levels.
Is CELULARITY INC-A (CELU) expected to grow?
The Revenue of CELULARITY INC-A (CELU) is expected to decline by -68.68% in the next year. Check the estimates tab for more information on the CELU EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CELULARITY INC-A (CELU) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CELU, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CELU, evaluating the profitability, health, valuation and growth aspects
- CELULARITY INC-A (CELU) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CELULARITY INC-A (CELU) Sales and EPS estimates to see what analysts future expectations are.
- CELULARITY INC-A (CELU) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CELULARITY INC-A (CELU) Insider and Institutional Ownership to learn about the owners and their transactions.
- CELULARITY INC-A (CELU) Stock Chart to make your own analysis
- CELULARITY INC-A (CELU) Latest news and press-releases to stay up to date.
Does CELULARITY INC-A (CELU) stock pay dividends?
CELU does not pay a dividend.
When does CELULARITY INC-A (CELU) report earnings?
CELULARITY INC-A (CELU) will report earnings on 2025-07-28, after the market close.
What is the Price/Earnings (PE) ratio of CELULARITY INC-A (CELU)?
CELULARITY INC-A (CELU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.52).
What is the Short Interest ratio of CELULARITY INC-A (CELU) stock?
The outstanding short interest for CELULARITY INC-A (CELU) is 1.74% of its float. Check the ownership tab for more information on the CELU short interest.
CELU Technical Analysis
CELU Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CELU. Both the profitability and financial health of CELU have multiple concerns.
CELU Financial Highlights
Over the last trailing twelve months CELU reported a non-GAAP Earnings per Share(EPS) of -1.52. The EPS increased by 85.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.21% | ||
| ROE | -202.85% | ||
| Debt/Equity | 2.47 |
CELU Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CELU. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -62.86% and a revenue growth -68.68% for CELU